Kenneth Hoberman - SEC Form 4 Insider Trading Activity
Summary
Updated Aug 4, 2026
Kenneth Hoberman has filed 2 SEC Form 4 filings across 2 companies in the last 90 days.
Profile
Kenneth Hoberman serves as Director of TG THERAPEUTICS, INC. (TGTX). Hoberman has also held reporting roles at Nuvectis Pharma, Inc. (NVCT). Hoberman has reported 3 insider filings with the SEC since 2025. The most recent filing was in June 2026.
| Role | Director |
|---|---|
| Notability | 26/100 |
Board memberships
- TG THERAPEUTICS, INC.
- Nuvectis Pharma, Inc.
Reported roles
- Director
- Director
Trading Pattern
InsiderAlpha's records for Kenneth Hoberman go back to 2025: 3 primary Form 4 filings, an average of 1.5 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Career & Filing History
Every role Kenneth Hoberman has reported on a Form 4, reconstructed from the filings themselves - reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
- Director at TG THERAPEUTICS, INC. (TGTX) - 2 filings, 2025 to 2026
- Director at Nuvectis Pharma, Inc. (NVCT) - 1 filing, 2026
Recent Transactions
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-12 | NVCT | Nuvectis Pharma, Inc. | A - Grant or award | 35.0K | $0.00 | |
| 2025-06-12 | TGTX | TG THERAPEUTICS, INC. | A - Grant or award | 14.7K | $0.00 |
Companies - Last 90 Days
- TG THERAPEUTICS, INC. (TGTX) - 1 filing, last 2026-06-15
- Nuvectis Pharma, Inc. (NVCT) - 1 filing, last 2026-06-12
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades at the companies Kenneth Hoberman has recently filed at. Multiple unrelated insiders buying the same stock within a short window - cluster buying - has historically been one of the strongest Form 4 signals.
- Marlio Charles Mosseri - $1.87M of NVCT open-market activity in the last 12 months
- Sagar Lonial - $672K of TGTX open-market activity in the last 12 months
- Ron Bentsur - $279K of NVCT open-market activity in the last 12 months
- Yann Echelard - $163K of TGTX open-market activity in the last 12 months
- Juan Sanchez - $75K of NVCT open-market activity in the last 12 months
- Matthew L. Kaplan - $64K of NVCT open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
- James M. Kilts
- Richard D. Kinder
- Steven B. Klinsky
- Adam Koppel
- Kenneth Krogulski
- L1 Capital Pty Ltd
- LAZARUS ENERGY HOLDINGS, LLC
- Sang Young Lee
Frequently Asked Questions
Who is Kenneth Hoberman?
Kenneth Hoberman serves as Director of TG THERAPEUTICS, INC. (TGTX). Hoberman has also held reporting roles at Nuvectis Pharma, Inc. (NVCT). Hoberman has reported 3 insider filings with the SEC since 2025. The most recent filing was in June 2026.…
How many SEC Form 4 filings has Kenneth Hoberman submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Where can I see all of Kenneth Hoberman's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Open the live Kenneth Hoberman profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.